Yamazaki M, Fukuoka H, Nagata O, Kato H, Ito Y, Terasaki T, Tsuji A
Research Department, Hokuriku Seiyaku Co., Ltd., Fukui, Japan.
Biol Pharm Bull. 1994 May;17(5):676-9. doi: 10.1248/bpb.17.676.
The blood-brain barrier (BBB) permeability of mepyramine was measured by the carotid injection technique to elucidate the transport mechanism of an H1-antagonist in the central nervous system. Mepyramine was found to enter the brain by saturable and carrier-mediated transport. The in vivo kinetic parameters were estimated as follows: the maximum uptake rate (Jmax) was 7.12 +/- 1.37 mumol/min/g of brain, the Michaelis constant (Kt) was 4.40 +/- 2.00 mM, and the nonsaturable first order rate (Kd) was 0.28 +/- 0.02 ml/min/g of brain. The mepyramine transport was not inhibited either by nutrients or by choline, hemicholinium-3, though it was inhibited by the classical H1-antagonists such as diphenhydramine, diphenylpyraline, and also by propranolol. The above inhibitory effects suggest that a transport system different from the amine transport system exists for the BBB transport of mepyramine, and that this transporter is common not only for H1-antagonists but also for basic drugs.
通过颈动脉注射技术测定了美吡拉敏的血脑屏障(BBB)通透性,以阐明H1拮抗剂在中枢神经系统中的转运机制。发现美吡拉敏通过可饱和的载体介导转运进入大脑。体内动力学参数估计如下:最大摄取率(Jmax)为7.12±1.37 μmol/min/g脑,米氏常数(Kt)为4.40±2.00 mM,非饱和一级速率(Kd)为0.28±0.02 ml/min/g脑。美吡拉敏的转运不受营养物质或胆碱、半胱氨酸-3的抑制,尽管它受到经典H1拮抗剂如苯海拉明、二苯拉林以及普萘洛尔的抑制。上述抑制作用表明,美吡拉敏的BBB转运存在一种不同于胺转运系统的转运系统,并且这种转运体不仅对H1拮抗剂而且对碱性药物都是通用的。